New pill cocktail plus procedure shows promise for untreatable liver cancer
NCT ID NCT07309419
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This study tests whether adding a three-drug pill regimen to a standard liver cancer procedure (TACE) helps people with liver cancer that cannot be surgically removed live longer compared to the usual approach of TACE plus targeted therapy and immunotherapy. About 222 adults who have not had prior liver cancer treatment will take part. The main goal is to see if the new combination improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.